poisar

Stocks · News reference

Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back

Chandrima Sanyal

JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

ABBVGLDJNJLLYMRKVHTXBIXLV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Brendan Coffey

    Is the iShares Pharmaceuticals ETF or iShares Healthcare ETF the Better Fund for 2026?

    The article compares two healthcare-focused ETFs from iShares: IHE (Pharmaceuticals ETF) with 55 holdings and IYH (Healthcare ETF) with 100 holdings. While IHE delivered stronger 1-year returns of 50% versus IYH's 27.4%, the article recommends IYH as the better choice due to superior 3- and 5-year performance, greater diversification, and larger asset base of $3.9B. Both funds have identical 0.37% expense ratios.

    IHEIYHLLYJNJABBV
  2. James Halley

    Move Aside, Pfizer: This Stock Is the Smarter Dividend Buy Right Now

    While Pfizer offers a higher dividend yield of 6.1%, AbbVie is positioned as the superior long-term dividend stock. AbbVie has demonstrated stronger revenue growth (138% over a decade vs. Pfizer's 18%), is a Dividend King with 53 consecutive years of dividend increases, and has successfully navigated the loss of Humira exclusivity through home-grown replacements Skyrizi and Rinvoq. In contrast, Pfizer faces significant patent cliff exposure between 2026-2028 with $17-18 billion in annual revenue at risk from generic competition.

    ABBVPFE
  3. Na

    Lilly Builds Neuroscience into a New Long-Term Growth Driver

    Eli Lilly's neuroscience business, currently representing only 2% of revenues, is experiencing strong 32% growth with key products Kisunla and Emgality. The company is aggressively expanding its neuroscience pipeline through acquisitions including AtaiBeckley for treatment-resistant depression therapies, positioning neuroscience as a potential long-term growth driver to diversify beyond its dominant cardiometabolic business.

    LLYBIIBTEVANVSPFE